

Family Control Group, Rosemont, Illinois, and acquire voting shares of Taylor Capital Group, Inc., Rosemont, Illinois, and thereby indirectly acquire voting shares of Cole Taylor Bank, Chicago, Illinois.

Board of Governors of the Federal Reserve System, January 3, 2012.

Robert deV. Frierson,

Deputy Secretary of the Board.

[FR Doc. 2012-71 Filed 1-5-12; 8:45 am]

BILLING CODE 6210-01-P

FEDERAL RESERVE SYSTEM

Formations of, Acquisitions by, and Mergers of Bank Holding Companies

The companies listed in this notice have applied to the Board for approval, pursuant to the Bank Holding Company Act of 1956 (12 U.S.C. 1841 *et seq.*) (BHC Act), Regulation Y (12 CFR part 225), and all other applicable statutes and regulations to become a bank holding company and/or to acquire the assets or the ownership of, control of, or the power to vote shares of a bank or bank holding company and all of the banks and nonbanking companies owned by the bank holding company, including the companies listed below.

The applications listed below, as well as other related filings required by the Board, are available for immediate inspection at the Federal Reserve Bank indicated. The application also will be available for inspection at the offices of the Board of Governors. Interested persons may express their views in writing on the standards enumerated in the BHC Act (12 U.S.C. 1842(c)). If the proposal also involves the acquisition of a nonbanking company, the review also includes whether the acquisition of the nonbanking company complies with the standards in section 4 of the BHC Act (12 U.S.C. 1843). Unless otherwise noted, nonbanking activities will be conducted throughout the United States.

Unless otherwise noted, comments regarding each of these applications must be received at the Reserve Bank indicated or the offices of the Board of Governors not later than February 2, 2012.

A. Federal Reserve Bank of Cleveland (Nadine Wallman, Vice President) 1455 East Sixth Street, Cleveland, Ohio 44101-2566:

1. *KeyCorp*, Cleveland, Ohio; to retain, in a fiduciary capacity, 9.75 percent of the outstanding voting shares of Mechanics Financial Corporation, and thereby retain Mechanics Savings Bank, both in Mansfield, Ohio.

B. Federal Reserve Bank of Kansas City (Dennis Denney, Assistant Vice

President) 1 Memorial Drive, Kansas City, Missouri 64198-0001:

1. *Teton Financial Services, LLC*, Wilson, Wyoming; to become a bank holding company by acquiring 100 percent of the voting shares of Rocky Mountain Bank, Wilson, Wyoming.

Board of Governors of the Federal Reserve System, January 3, 2012.

Robert deV. Frierson,

Deputy Secretary of the Board.

[FR Doc. 2012-69 Filed 1-5-12; 8:45 am]

BILLING CODE 6210-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Meeting of the Advisory Council on Alzheimer's Research, Care, and Services

AGENCY: Assistant Secretary for Planning and Evaluation, HHS.

ACTION: Notice of meeting.

SUMMARY: This notice announces public meeting of the Advisory Council on Alzheimer's Research, Care, and Services (Advisory Council). Notice of these meetings is given under the Federal Advisory Committee Act (5 U.S.C. App. 2, section 10(a)(1) and (a)(2)). The Advisory Council on Alzheimer's Research, Care, and Services will provide advice on how to prevent or reduce the burden of Alzheimer's disease and related dementias on people with the disease and their caregivers. A representative from the Department of Health and Human Services (HHS) will present an overview of the Draft National Plan to Address Alzheimer's Disease. The chairs of the three subcommittees (Research, Clinical Care, Long-Term Services and Supports) will summarize the feedback from their subcommittees and suggest recommendations for discussion among the full Advisory Council. The Advisory Council will discuss and, as appropriate, vote upon recommendations to the Secretary of HHS on the Draft National Plan to Address Alzheimer's Disease.

DATES: January 17, 2012 from 9:30 a.m. to 4 p.m. and January 18, 2012 from 9 a.m. to 2 p.m.

ADDRESSES: The meeting will be held at the U.S. Department of Health and Human Services, 200 Independence Avenue SW., Room 800, Washington, DC 20201.

Comments: Time is allocated on the agenda to hear public comments. In lieu of oral comments, formal written comments may be submitted for the record to Helen Lamont, OASPE, 200

Independence Avenue SW., Room 424E, Washington, DC 20201. Comments may also be sent to napa@hhs.gov. Those submitting written comments should identify themselves and any relevant organizational affiliations.

FOR FURTHER INFORMATION CONTACT:

Helen Lamont (202) 690-7996, helen.lamont@hhs.gov. **NOTE:** Seating may be limited. Those wishing to attend the meeting must call or email Dr. Lamont by Tuesday, January 10, 2012, so that their names may be put on a list of expected attendees and forwarded to the security officers at the Department of Health and Human Services. Any interested member of the public who is a non-U.S. citizen should include this information at the time of registration to ensure that the appropriate security procedure to gain entry to the building is carried out. Although the meeting is open to the public, procedures governing security and the entrance to Federal buildings may change without notice.

SUPPLEMENTARY INFORMATION: Topics of the Meeting: The Advisory Council will discuss the Draft National Plan to Address Alzheimer's Disease. The Advisory Council is specifically charged with making recommendations to the Secretary on priorities for the National Plan. As appropriate, the Advisory Council will make, discuss, and vote on such recommendations.

Procedure and Agenda: This meeting is open to the public. A representative from the Department of Health and Human Services (HHS) will present an overview of the Draft National Plan to Address Alzheimer's Disease. The chairs of the three subcommittees (Research, Clinical Care, Long-Term Services and Supports) will summarize the feedback from their subcommittees and suggest recommendations for discussion among the full Advisory Council. The Advisory Council will discuss and, as appropriate, vote upon recommendations to the Secretary of HHS on the Draft National Plan to Address Alzheimer's Disease. The Advisory Council will also discuss how to engage stakeholders outside of the Federal government in the writing and implementation of the National Plan. The Advisory Council will allow an open public session for any attendee to address issues or topics that should be addressed in the National Plan.

Authority: 42 U.S.C. 11225; Section 2(e)(3) of the National Alzheimer's Project Act. The panel is governed by provisions of Public Law 92-463, as amended (5 U.S.C. Appendix 2), which sets forth standards for the formation and use of advisory committees.

Dated: December 19, 2011.

Sherry Glied,

Assistant Secretary for Planning and Evaluation.

[FR Doc. 2012–30 Filed 1–5–12; 8:45 am]

BILLING CODE P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health Statement of Organization, Functions, and Delegations of Authority

Part N, National Institutes of Health (NIH), of the Statement of Organization, Functions, and Delegations of Authority for the Department of Health and Human Services (40 FR 22859, May 27, 1975, as amended most recently at 66 FR 6617, January 22, 2001, and redesignated from Part HN as Part N at 60 FR 56605, November 9, 1995), is amended as set forth below to establish the National Center for Advancing Translational Science (NCATS), to abolish the National Center for Research Review (NCRR), and to establish organizational components within National Institute of General Medical Sciences (NIGMS), National Institute on Minority Health and Health Disparities (NIMHD) and the NIH Office of the Director (OD).

Section N–8, Organization and Functions, is amended as follows: Immediately after the paragraph headed “Division of Program Coordination and Integration” (N 875, formerly HN 875), insert the following:

National Center for Advancing Translational Sciences (NCATS) (N 9, formerly HN 9) (1) Provides leadership for a national program to advance the discipline of translational science and catalyze the generation of innovative methods and technologies that will enhance the development, testing, and implementation of diagnostics and therapeutics across a wide range of human diseases and conditions; (2) conducts intramural research; (3) supports and coordinates research projects through research grants, contracts, and other mechanisms; (4) supports training in translational sciences; (5) collaborates with organizations and other institutions engaged in translational research and training activities; and (6) collects and disseminates research findings and related information.

Office of the Director (OD) (N 91, formerly HN 91) (1) Develops and provides leadership for the Center’s translational science programs; (2) manages and directs executive-level activities and functions; (3) provides

policy guidance and overall operational coordination for the organizational units within NCATS; and (4) manages critical points of contact and related information flows to respond to external inquiries.

Division of Pre-Clinical Innovation (DPI) (N 92, formerly HN 92) (1) Plans, conducts, and supports research across the pre-clinical phases of the translational science spectrum; (2) plans, conducts, and supports research to develop new methods and technologies to enhance pre-clinical processes; (3) plans, conducts, and supports research to evaluate existing and developing approaches, technologies, and processes in the pre-clinical spectrum; (4) supports training programs relevant to pre-clinical phases of translational science; (5) allocates resources to pre-clinical extramural and intramural investigators; (6) collaborates with ICs and the scientists they support; and (7) consults with stakeholders, including patients, industry, and regulators.

Division of Clinical Innovation (DCI) (N 93, formerly HN 93) (1) Plans, conducts, and supports research across the clinical phases of the translational science spectrum; (2) plans, conducts, and supports research to develop new methods and technologies to enhance clinical processes; (3) plans, conducts, and supports research to evaluate existing and developing approaches, technologies, and processes in the clinical spectrum; (4) supports training programs relevant to clinical phases of translational science; (5) allocates resources to clinical extramural and intramural investigators; (6) collaborates with ICs and the scientists they support; and (7) consults with stakeholders, including patients, industry, and regulators.

Executive Office (EO) (N 912, formerly HN 912) (1) Directs the administrative management and financial management operations of NCATS; (2) develops, administers, and directs NCATS’ internal control processes; (3) oversees development of and administers NCATS policies and procedures for administrative, program management, and information technology activities; and (4) oversees personnel management and workforce planning.

Office of Grants Management and Scientific Review (OGMSR) (N 913, formerly HN 913) (1) Provides advice and assistance to the Director of NCATS, NCATS Division Directors, and other NCATS officials on issues related to policy and procedures for extramural activities; (2) provides oversight and direction for scientific review and grants

management activities of NCATS; (3) coordinates NCATS small business research programs and other special grants programs; (4) manages the operations of the national advisory council for NCATS; and (5) provides coordination, support, and staff services for committee management.

Office of Rare Diseases Research (ORDR) (N 914, formerly, HN 914) (1) Guides and coordinates NIH-wide activities involving research into combating and treating the broad array of rare (orphan) diseases; (2) manages the NIH Rare Diseases and Orphan Products Coordinating Committee (Trans-NIH Rare Diseases Working Group); (3) develops and maintains a centralized database on rare diseases; (4) coordinates and provides liaison with Federal and non-Federal national and international organizations concerned with rare disease research and orphan products development; (5) advises the OD/NIH on matters relating to NIH-sponsored research activities that involve rare diseases and conditions; and (6) responds to requests for information on highly technical matters and matters of public policy relative to rare diseases and orphan products.

Office of Policy, Communications, and Strategic Alliances (OPCSA) (N 915, formerly, HN 915) (1) Provides leadership and direction to the planning, coordinating, reporting, analytical, evaluative, and legislative functions that support NCATS program development, science policy formulation, and overall program direction and decision-making activities of the NCATS executive staff; (2) advises the NCATS Director on policy matters pertaining to NCATS scientific programs; (3) communicates information about NCATS programs and accomplishments to a wide range of audiences; (4) advises the NCATS Director on effective communications strategies; (5) fosters relationships and partnerships with stakeholders; (6) assists in the development of content for internal and external Web sites and audiences; (7) develops and executes a strategy for education and training for the disciplines that constitute translational science; (8) facilitates and supports partnerships with NIH OD, other ICs, patient groups, other governmental agencies, nonprofits and the private sector to achieve the goals of the Center; and (9) oversees and manages NCATS technology transfer activities including overseeing NCATS intellectual property, patent, and licensing agreement portfolios.

Section N–D, Organization and Functions, is amended as follows: Immediately after the paragraph headed